Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...